Xspray Pharma AB (publ) (STO:XSPRAY)
10.10
+0.17 (1.71%)
Sep 2, 2026, 5:29 PM CET
Xspray Pharma AB Revenue
Xspray Pharma AB had revenue of 8.43M SEK in the quarter ending June 30, 2026, with 542.19% growth. This brings the company's revenue in the last twelve months to 12.19M, up 185.59% year-over-year. In the year 2025, Xspray Pharma AB had annual revenue of 6.43M with 206.87% growth.
Revenue (ttm)
12.19M
Revenue Growth
+185.59%
P/S Ratio
190.94
Revenue / Employee
102.75K
Employees
24
Market Cap
470.85M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.43M | 4.34M | 206.87% |
| Dec 31, 2024 | 2.10M | -29.67M | -93.40% |
| Dec 31, 2023 | 31.77M | 29.59M | 1,357.20% |
| Dec 31, 2022 | 2.18M | 1.52M | 232.32% |
| Dec 31, 2021 | 656.00K | -708.00K | -51.91% |
| Dec 31, 2020 | 1.36M | 990.00K | 264.71% |
| Dec 31, 2019 | 374.00K | 11.00K | 3.03% |
| Dec 31, 2018 | 363.00K | -793.00K | -68.60% |
| Dec 31, 2017 | 1.16M | -20.04M | -94.55% |
| Dec 31, 2016 | 21.19M | 16.57M | 358.36% |
| Dec 31, 2015 | 4.62M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cantargia AB | 317.31M |
| Sprint Bioscience AB | 138.95M |
| AlzeCure Pharma AB | 97.33M |
| Oncopeptides AB | 95.15M |
| IRLAB Therapeutics AB | 79.33M |
| Intervacc AB | 18.11M |
| Corline Biomedical AB | 11.85M |
| FluoGuide | 404.33K |
Xspray Pharma AB News
- 13 days ago - Xspray Pharma AB Transcript: FDA announcement - Transcripts
- 13 days ago - Xspray Pharma AB Press release: FDA announcement - Filings
- 4 weeks ago - Xspray Pharma AB Quarterly report: Q2 2026 - Filings
- 4 months ago - Xspray Pharma AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Xspray Pharma AB Annual report: Q4 2025 - Filings
- 6 months ago - Xspray Pharma AB Quarterly report: Q4 2025 - Filings
- 10 months ago - Xspray Pharma AB Quarterly report: Q3 2025 - Filings
- 10 months ago - Xspray Pharma AB Press release: FDA announcement - Filings